IVIG to help prevent infections after CAR-T treatment
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can understand the study to give consent (or your legal representative can, if needed)
- You will receive (or recently received) an FDA-approved CD19 CAR-T cell treatment for a blood cancer
- Your IgG level (a key infection-fighting protein) is low—less than 600 mg/dL within the last 3 months, unless you’re already getting IVIG
- You do not have a serious known allergy to IVIG ingredients
- You have not had serious side effects from IVIG in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
This trial tests whether giving immunoglobulin (a treatment that boosts your antibodies) can help people who developed very low antibody levels after CAR T-cell therapy for cancer. It may help prevent infections and improve recovery.
This study compares two ways to help prevent infections after CAR-T cell therapy: regular antibody infusions (immunoglobulins) versus taking antibiotics. If you have low antibody levels after CAR-T treatment, this trial may help decide which approach works better for you.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.